title: DNA probe technology: implications for service planning in Britain.
abstract: For certain genetic conditions DNA testing identifies carriers and determines the risk status of foetuses, thus helping parents to make more informed prenatal decisions. Data, collected from three genetic centres in England and Wales from August 1986 to July 1990, are used to describe trends in demand for DNA testing, the impact of DNA tests on carrier risk assessment, and the use of DNA tests in relation to pregnancy outcome. Altogether the data include 23,388 subjects and 681 pregnancies in 8738 families divided into five cohorts by year of entry and referral. The most frequent gene disorders referred to the genetic centres are currently being tested or will soon be tested. For these disorders the initial high level of activity has declined and may have reached steady state. Demand for DNA services is high for cystic fibrosis and Duchenne muscular dystrophy, intermediate for Huntington's disease, and low for adult polycystic kidney disease, phenylketonuria and tuberous sclerosis. Based on these findings we suggest that demand for DNA tests will be high in serious, untreatable and slow progressing conditions with early onset; intermediate for conditions affecting intellect and neurological integrity with later onset; and low for treatable, late-onset conditions, or those for which there is evidence of heterogeneity, and variable penetrance. It would be helpful to assess the extent to which this view of demand is confirmed when the new disorders being DNA tested are considered and for the pattern of activity of DNA testing for some types of cancer. Since no DNA centre could offer a fully comprehensive testing service, it is recommended that a structure is created to audit overall activity, assist in policy formulation, and influence supraregional service organisation, in order that the spread of DNA services be planned as effectively as possible. This structure would facilitate monitoring of the evolution of contract specifications agreed by commissioners and providers on a regional basis.
authors.affiliation: Department of Public Health Medicine, United Medical School of Guy's Hospital, London, UK.
authors.forename: R J
authors.initials: RJ
authors.lastname: Rona
authors.forename: A V
authors.initials: AV
authors.lastname: Swan
authors.forename: R
authors.initials: R
authors.lastname: Beech
authors.forename: O M
authors.initials: OM
authors.lastname: Wilson
authors.forename: F B
authors.initials: FB
authors.lastname: Kavanagh
authors.forename: C
authors.initials: C
authors.lastname: Brown
authors.forename: C
authors.initials: C
authors.lastname: Axtell
authors.forename: S
authors.initials: S
authors.lastname: Mandalia
mesh_terms: D000293:Adolescent; D000328:Adult; D015342:DNA Probes; D005260:Female; D006580:Genetic Carrier Screening; D005820:Genetic Testing / Q000458:organization & administration / Q000706:statistics & numerical data*; D006285:Health Planning; D006291:Health Policy; D006301:Health Services Needs and Demand / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000706:statistics & numerical data; D012041:Regional Medical Programs / Q000458:organization & administration; D012307:Risk Factors; D006113:United Kingdom
chemical_list: D015342:DNA Probes